| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Livongo | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $237.65M | Series E | 4/23/2018 | $105M | $796.49M | $8.30 | General Catalyst, KinnevikMerck, Global Health Innovation Fund, Wanxiang America, M12, Echo Health Ventures, Sapphire Ventures, Zaffre Investments, 7wire Ventures, Kleiner Perkins and Draper Fisher Jurvetson Management | ||||
 | One Medical Group | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $437.68M | Series I | 8/22/2018 | $250M | $1.5B | $12.43 | The Carlyle Group | ||||
 | Paragon 28 | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Revolution Medicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $351.77M | $35.83 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | ||||
 | Sirnaomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Theseus Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | 10x Genomics, Inc. | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $222.59M | Series D-1 | 1/7/2019 | $35M | $1.34B | $12.73 | Meritech Capital, Fidelity, Wells Fargo | ||||
 | Bioventus | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Contineum Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $133.61M | Series C | 2/11/2021 | $80.4M | $244.63M | $2.68 | Perceptive Advisors, Franklin Templeton, Casdin Capital, Samsara BioCapital, Suvretta Capital, Red Tree Venture Capital, Versant Ventures, Sectoral Asset Management, Cleva Pharma | ||||
 | Erasca | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | IsoPlexis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $161.52M | Series D | 1/7/2021 | $92.5M | $348.21M | $76.92 | Perceptive Advisors, Ally Bridge Group, BlackRock | ||||
 | Kronos Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Recursion Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Tempest Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Tyra Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $157.64M | Series B | 3/31/2021 | $106.3M | $348.37M | $27.43 | Nextech Invest, Cormorant Asset Management, BVF Partners, Janus Henderson Investors, Logos, Alta Partners, RA Capital, Boxer Capital, Cannaan | ||||
 | Alumis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.66B | Series C | 3/6/2024 | $259M | $702.67M | $3.14 | Foresite Capital, Samsara BioCapital, venBio Partners, Cormorant Asset Management, SR One, Lilly Asia Ventures, Nextech, Ally Bridge Group, HBM Healthcare Investments, Omega Funds, Piper Heartland Healthcare, AyurMaya Capital Management | ||||
 | Arcellx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $235.48M | Series C | 4/13/2021 | $120M | $377.76M | $2.10 | Samsara BioCapital, CAM Capital, Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta, Terra Magnum Capital Partners, New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech, Clough Capital | ||||
 | Aura Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $225.08M | Series E | 3/22/2021 | $80.48M | $283.03M | $0.78 | Matrix Capital Management, Surveyor Capital, Rock Springs Capital, Adage Capital Management LP, Velosity Capital, Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital, Columbus Venture Partners | ||||
 | Broncus Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Ceribell | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.6M | Series C-1 | 9/22/2022 | $100.39M | $328.64M | $11.49 | Longitude Capital, The Rise Fund, RA Capital Management, Redmile Group, Red Tree Venture Capital, Ally Bridge Group | ||||
 | Compass Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Cytek | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Edgewise Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||